The 10 US Biosimilar Launches That Could Drive Big Savings By 2027
Executive Summary
Biosimilar versions of drugs like Humira, Stelara and Eylea are among the products that could generate cumulative sales of $129bn over the next five years, according to IQVIA.
You may also be interested in...
Stelara Biosimilars In Wings, Will Proposed Red Tape Elimination Act Aid Biosimilars Push?
As Stelara biosimilars wait in the wings, proposed legislation in the US could ease the path to commercialization. The Draft Red Tape Elimination Act aims to remove a requirement for switching studies. Opposition to the bill is expected, but if passed how much will the Act move the biosimilars needle in the country? Scrip spoke to experts to gauge its likely impact.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: 10 big upcoming US biosimilar launches; Kisqali strikes gold in early adjuvant breast cancer; Zolgensma shows the promise and limitations of gene therapy; Chinese biotechs advancing multiple ADCs; and Scrip Asks about diversity, equity and inclusion in pharma.
‘Inertia’ Likely To Restrain Biosimilar Humira In US Market, Experts Say
PBM contracting and payer formulary placement for branded Humira signal headwinds for biosimilar versions in the US, according to participants in an IQVIA-sponsored panel.